Lifecore Biomedical Inc
NASDAQ:LFCR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lifecore Biomedical Inc
Income from Continuing Operations
Lifecore Biomedical Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lifecore Biomedical Inc
NASDAQ:LFCR
|
Income from Continuing Operations
-$18m
|
CAGR 3-Years
39%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Hershey Co
NYSE:HSY
|
Income from Continuing Operations
$883.3m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
6%
|
|
|
Tyson Foods Inc
NYSE:TSN
|
Income from Continuing Operations
$231m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-16%
|
|
|
Kellogg Co
NYSE:K
|
Income from Continuing Operations
$1.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
13%
|
|
|
Kraft Heinz Co
NASDAQ:KHC
|
Income from Continuing Operations
-$5.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mondelez International Inc
NASDAQ:MDLZ
|
Income from Continuing Operations
$2.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-11%
|
|
Lifecore Biomedical Inc
Glance View
Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. The company is headquartered in Chaska, Minnesota and currently employs 689 full-time employees. The firm offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials, as well as the manufacture of pharmaceutical-grade Hyaluronic Acid. The company provides complete CDMO services for injectable pharmaceuticals and medical devices. The Company’s services include sodium hyaluronate, development, manufacturing, and analytical services. The company offers a range of average molecular weights and custom modifications for research and development (R&D), clinical, and commercial applications. The Company’s therapeutic applications include drug delivery, biomaterials, ophthalmology, orthopedics, aesthetics, oncology, and pain management. Its development capabilities include formulation, sterile filtration, filling, packaging, testing, and secondary sterilization.
See Also
What is Lifecore Biomedical Inc's Income from Continuing Operations?
Income from Continuing Operations
-18m
USD
Based on the financial report for Dec 31, 2025, Lifecore Biomedical Inc's Income from Continuing Operations amounts to -18m USD.
What is Lifecore Biomedical Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
0%
Over the last year, the Income from Continuing Operations growth was -19%. The average annual Income from Continuing Operations growth rates for Lifecore Biomedical Inc have been 39% over the past three years .
